A meta-analysis of four large genome-wide association studies turned up 11 new risk genes for Alzheimer’s disease.
More evidence that an antisense RNA strategy might work for certain types of ALS and FTD.
A repeat expansion that causes neurodegenerative disease is transcribed both forward and backward, producing sense and antisense RNAs and multiple polypeptides.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Some neurons stand out in the crowd. Researchers report that genomic variation among neurons in the brain is more common than originally thought.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
A proof-of-concept study suggests that amyloid imaging will offer insights into traumatic brain injury.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
Once branded as a difficult target, β-secretase has become the crowd favorite. But might pharma have to cool its jets?
As new substrates and functions for BACE continue to emerge, scientists worry about adverse effects of blocking the protease.
Researchers at a meeting on BACE shared concerns that blocking the protease in adults might have unexpected consequences.
Researchers at BACE meeting explore how trafficking and degradation of the protease relate to amyloid pathology in AD.